Possible renoprotective mechanisms of SGLT2 inhibitors
Treatment with a sodium glucose cotransporter 2 (SGLT2) inhibitor in patients with chronic kidney disease reduces the renal risk independent of changes in blood glucose concentrations and blood pressure. However, the precise mechanism responsible for this SGLT2 inhibitor-induced renoprotective effec...
Main Authors: | Akira Nishiyama, Kento Kitada |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2023.1115413/full |
Similar Items
-
Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease
by: John S. Clemmer, et al.
Published: (2023-11-01) -
SGLT2 inhibitors in diabetic and non-diabetic kidney transplant recipients: current knowledge and expectations
by: Erietta Polychronopoulou, et al.
Published: (2024-04-01) -
Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect
by: Raphaëlle Corremans, et al.
Published: (2023-05-01) -
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
by: Roko Skrabic, et al.
Published: (2022-10-01) -
SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
by: Carlo Garofalo, et al.
Published: (2019-06-01)